- Name
- Description
- Cat#
- Pricings
- Quantity
Catalogue number
CYT-307
Synonyms
BAFF, BLYS, CD257, TALL1, THANK, ZTNF4, TALL-1, TNFSF20, TNFSF13B, B-cell Activating Factor.
Introduction
BAFF binds to tnfrsf13b/taci and tnfrsf17/bcma. Tnfsf13/april binds to the same 2 receptors, together, they form a 2 ligands -2 receptors pathway involved in the stimulation of b- and t-cell function and the regulation of humoral immunity. A third b-cell specific baff-receptor (baffr/br3) promotes the survival of mature b-cells and the b-cell response.
B Lymphocyte Stimulator functions as a potent B-cell growth factor in costimulation assays.
Administration of BAFF Human recombinant to mice disrupts splenic B-cell and T-cell zones and results in elevated levels of serum immunoglobulin.
B Lymphocyte Stimulator functions as a potent B-cell growth factor in costimulation assays.
Administration of BAFF Human recombinant to mice disrupts splenic B-cell and T-cell zones and results in elevated levels of serum immunoglobulin.
Description
BAFF Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 153 amino acids and having a molecular mass of 17007 Dalton.
The BAFF is purified by proprietary chromatographic techniques.
The BAFF is purified by proprietary chromatographic techniques.
Source
Escherichia Coli.
Physical Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation
Lyophilized from a 0.2µm filtered concentrated solution in PBS, pH 7.0.
Solubility
It is recommended to reconstitute the lyophilized BAFF in sterile 18M-cm H2O not less than 100µg/ml, which can then be further diluted to other aqueous solutions.
Stability
Lyophilized BAFF although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution BAFF should be stored at 4°C between 2-7 days and for future use below -18°C.
Please prevent freeze-thaw cycles.
Please prevent freeze-thaw cycles.
Purity
Greater than 95.0% as determined by:
(a) Analysis by RP-HPLC.
(b) Analysis by SDS-PAGE.
(a) Analysis by RP-HPLC.
(b) Analysis by SDS-PAGE.
Amino acid sequence
MAVQGPEETV TQDCLQLIAD SETPTIQKGS YTFVPWLLSF KRGSALEEKE
NKILVKETGY FFIYGQVLYT DKTYAMGHLI QRKKVHVFGD ELSLVTLFRC
IQNMPETLPN NSCYSAGIAK LEEGDELQLA IPRENAQISL DGDVTFFGAL KLL.
Biological Activity
The activity is determined by a mouse splenocyte survival assay. The ED50 for this effect is 0.5-2.0µg/ml.
Safety Data Sheet
Usage
ProSpec's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Background
B-cell Activating Factor Human Recombinant: Unleashing the Potential of a Key Immunomodulatory Molecule
Abstract:
B-cell Activating Factor (BAFF) human recombinant is a critical immunomodulatory molecule that plays a crucial role in B-cell development, maturation, and survival. This research paper provides a comprehensive analysis of BAFF, including its characteristics, signaling pathways, and potential therapeutic applications. Additionally, innovative methodologies for the production and optimization of BAFF human recombinant are proposed, shedding light on its future implications in the field of immunotherapy.
Introduction:
The immune system's intricate orchestration relies on numerous factors, including BAFF, which governs B-cell function and antibody production. This paper explores the unique features of BAFF and presents novel approaches for its production and optimization, aiming to uncover its therapeutic potential.
Characteristics and Signaling Pathways:
BAFF is a cytokine belonging to the tumor necrosis factor (TNF) superfamily, comprising 285 amino acids. It interacts with three receptors: BAFF receptor (BAFF-R), transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI), and B-cell maturation antigen (BCMA). The engagement of BAFF with its receptors activates intracellular signaling pathways, including the nuclear factor-kappa B (NF-κB) and phosphoinositide 3-kinase (PI3K) pathways, leading to B-cell survival, maturation, and antibody production.
Production of BAFF Human Recombinant:
Efficient production methodologies are vital for harnessing the therapeutic potential of BAFF human recombinant. Various expression systems, including bacterial, yeast, and mammalian cell-based platforms, have been explored. Each system offers advantages and challenges, necessitating careful selection to achieve high yields and protein quality. Optimization strategies, such as codon optimization, fusion protein tags, and growth conditions, have been employed to enhance production efficiency. Purification techniques, including chromatography and affinity-based methods, have been optimized to isolate high-quality BAFF recombinant.
Potential Therapeutic Applications:
BAFF human recombinant holds significant promise in the field of immunotherapy. Dysregulation of BAFF signaling has been implicated in autoimmune diseases, such as systemic lupus erythematosus and rheumatoid arthritis. Thus, modulating BAFF activity using BAFF human recombinant may provide a therapeutic approach for these conditions. Moreover, BAFF has shown potential as a target for B-cell malignancies, and BAFF human recombinant may serve as an adjuvant therapy in combination with existing treatments.
Conclusion:
BAFF human recombinant represents a pivotal immunomodulatory molecule with diverse therapeutic applications in immunotherapy. Optimizing production methodologies and further understanding its signaling pathways will enhance its clinical utility. With its potential implications in autoimmune diseases and B-cell malignancies, BAFF human recombinant holds immense promise as an innovative therapeutic tool for immune-related disorders.
References
Bibliography:
- Schneider P. The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol. 2005;17(3):282-289.
- Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol. 2002;2(7):465-475.
- Mariette X, Roux S, Zhang J, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis. 2003;62(2):168-171.
- Stohl W. Therapeutic targeting of B cell activating factor (BAFF) in the B cell disorders of Sjogren's syndrome and systemic lupus erythematosus (SLE). Expert Rev Clin Immunol. 2017;13(2):155-166.
- Dillon SR, Gross JA, Ansell SM, et al. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov. 2006;5(3):235-246.